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Hypereosinophilic syndrome (HES) has generally been deﬁned as a peripheral blood eosinophil count
greater than 1500/mm3 and may be associated with tissue damage. Imatinib is customarily used as the
ﬁrst-line therapy for HES with gene abnormalities, such as PDGFRA or PDGFRB. We presented a case
where the patient was diagnosed with HES, with PDGFRB rearrangement. The patient began an
imatinib regimen after diagnosis and then developed resistance to imatinib. The combination of
dasatinib, methylprednisolone and hydroxyurea was administered to the patient as the salvage
therapy.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The eosinophilias encompass a broad range of nonhematologic
(secondary or reactive) and hematologic (primary, clonal) disorders
with potential for end-organ damage.1 Hypereosinophilic syn-
drome (HES) has generally been deﬁned as a peripheral blood
eosinophil count greater than 1500/mm3 and may be associated
with tissue damage.1 Overall, HES is a rare disease with an inci-
dence of approximately 0.036 per 100,000.2
After exclusion of secondary causes of eosinophilia, diagnostic
evaluation of primary eosinophilias relies on a combination of
morphologic review of the blood and marrow, standard cytoge-
netics, ﬂuorescent in situ hybridization, ﬂow immunocytometry,
and T-cell clonality assessment to detect histopathologic or clonal
evidence for an acute or chronic myeloid or lymphoproliferative
disorder.1
The classiﬁcation of eosinophilic diseases was revised in the
2008 World Health Organization categorization of myeloid neo-
plasms. In recognition of the growing list of recurrent, molecularly
deﬁned primary eosinophilias, a new major category was created,
“Myeloid and lymphoid neoplasms with eosinophilia andd Oncology, Department of
Shipai Road, Sec. 2, Taipei,
g).
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Society. Production and hosting byabnormalities of platelet-derived growth factor receptor alpha
(PDGFRA), platelet-derived growth factor receptor beta (PDGFRB),
or ﬁbroblast growth factor receptor 1 (FGFR1)” (Table 1).1
The success of imatinib in cases of chronic myelogenous leu-
kemia (CML) led to its empirical use in patients with HES who
exhibited signs suggestive of a myeloproliferative disorder since
2001. However, the effect of imatinib varied with gene abnormal-
ities in treating HES.3,4
As we know, some patients with CML develop resistance to
imatinib. In prospective cohorts, imatinib-treated FIP1L1-PDGFRA-
positive myeloid neoplasms were evaluated and resistance of
imatinib was rarely reported.5,6 Herein we have presented a case
diagnosed as HES with PDGFRB rearrangement that subsequently
developed resistance to imatinib.2. Case presentation
Initially, the 39-year-old woman presented to our facility with
fever, skin rash, and pneumonitis in February 2005 (Fig. 1). Her
hemogram showed a WBC of 30,100/mm3, Hb 13.7 g/dl, PLT
303000/mm3, seg 61%, lym 21%, mono 10%, and eos 8%. Her pul-
monary function test displayed normal ventilator function and
moderate reduction of gas exchange in May 2005. We had
administered pulse therapy (steroid) for 3e4 months but her
eosinophil counts remained persistently high. Then, she had been
noted as persistent hypereosinophilia (absolute eosinophil count
>1500/mm3) for more than 6 months. She received a lung biopsyElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1
2008 World Health Organization (WHO) classiﬁcation of myeloid malignancies.
1 Acute myeloid leukemia and related disorders
2 Myeloproliferative neoplasms (MPN)
 Chronic myelogenous leukemia, BCR-ABL1 positive
 Chronic neutrophilic leukemia
 Polycythemia vera
 Primary myeloﬁbrosis
 Essential thrombocythemia
 Chronic eosinophilic leukemia, not otherwise speciﬁed
 Mastocytosis
 Myeloproliferative neoplasms, unclassiﬁable
3 Myelodysplastic syndromes
 Refractory cytopenia with uni-lineage dysplasia
- Refractory anemia
- Refractory neutropenia
- Refractory thrombocytopenia
 Refractory anemia with ring sideroblasts
 Refractory cytopenia with uni-lineage dysplasia
 Refractory anemia with excess blasts (RAEB)
- RAEB-1
- RAEB-2
 Myelodysplastic syndrome with isolated del(5q)
 Myelodysplastic syndrome, unclassiﬁable
4 MDS/MPN
Chronic myelomonocytic leukemia
- CMML-1
- CMML-2
Atypical chronic myeloid leukemia, BCR-ABL1 negative
Juvenile myelomonocytic leukemia
MDS/MPN, unclassiﬁable
- Refractory anemia with ring sideroblasts and thrombocytosis (RARS-T)
Myeloid and lymphoid neoplasms associated with eosinophila and
abnormalities of PDGFRA, PDGFRB and FGFR1
5 Myeloid and lymphoid neoplasms associated with PDGFRA rearrangement
Myeloid neoplasms associated with PDGFRB rearrangement
Myeloid and lymphoid neoplasms associated with FGFR! abnormalities
Fig. 1. A chest X-ray showing mild inﬁltration with ground glass opacities in both
lower lungs in February, 2005 (Initial presentation).
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sinophils in the capillaries of the alveolar walls. She received both
bone marrow examination and bone marrow cytology, which
showed hypercellularity of approximately 80%, an M/E ratio of 4/1,
no excess blasts, no dysplastic changes, and eosinophilia of about
8% in November 2007. Subsequent to review of gastrointestinal
stromal tumors, her fusion gene was detected as t (5; 14)
KIAA1509-PDGFRB by PCR and the karyotype was t (3; 16) (p13;
q24), 16, þmar. Lab data were noted normal-range ESR 8 mm/h
and high-level IgE 1168 kU/L. Her abdominal sonogram detected
splenomegaly with long axis of about 12.8 cm. At that time, we
searched associated journals about HES for diagnosis.7 In the next
year, according to the 2008 World Health Organization (WHO)
Classiﬁcation of Myeloid Malignancies, the diagnosis of this pa-
tient was revised as “myeloid neoplasms associated with PDGFRB
rearrangement”. Besides, pneumonitis may be recognized as end-
organ damage (Fig. 2).
After diagnosis, the patient still complained of shortness
of breath and started to take imatinib 200 mg per day and
methylprednisolone 8 mg per day in November 2007 (Fig. 3).
This combination had lasted for 4 months, after which she then
kept using imatinib. Subsequent computer tomography (CT)
of the chest revealed gradual regression after imatinib use
(Fig. 4). Prior to admission to our facility, her disease had beenstable for 6 years (2008e2013). During this period, the fusion
gene PDGFRB had not been detected (from May 2008 through
August 2012).
Unfortunately, she suffered from progressive dyspnea and a CT
of her chest also revealed progressive pneumonitis in October 2013
(Fig. 5). Her WBC count was elevated to 13,400/mm3 (AEC 817/
mm3). However, her fusion gene PDGFRBwas still not detected. We
increased the dose of imatinib to 400 mg per day in November
2013. However, the symptoms did not improve. We arranged for a
re-biopsy of her lung lesion to investigate other possible etiology in
April 2014. The pathology still revealed “eosinophilic pneumonia
with cellular interstitial lymphoid cells inﬁltration”. Due to the
limitation of our laboratory, we could not detect the T674I muta-
tion. Then, we prescribed nilotinib 300 mg per day exclusively to
replace imatinib in June 2014. However, this change of drug
regimen still only produced a poor result. Her lung lesions were
getting worse and WBC count also increased to 21,400/mm3 (AEC
2268/mm3). We rechecked the fusion gene PDGFRB and the result
was negative. Dasatinib 70 mg per day was administered to replace
nilotinib in September 2014. After 2months, the disease activity did
not subside. Due to the patient's economy and choice, we decided
to use the combination of dasatinib 50 mg per day, methylpred-
nisolone 8 mg per day, and hydroxyurea 1000 mg per day. There-
after, her symptoms improved and AEC also decreased. A successive
CT of the chest was also consistent with clinical improvement
(Fig. 6).
Fig. 2. A CT of the chest showing ground glass opacities at the peripheral regions of RLL (B6), left lingual lobe and posterior basal segments of bilateral lower lobes with minimal
atoll sign at anterior basal segment of RLL in January, 2006. (Before imatinib 200 mg/day).
Fig. 3. A chest X-ray showing increased inﬁltration over bilateral lower lungs in
November, 2007 (Just before imatinib 200 mg/day).
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Clinically, HES may be separated into two subgroups: HES with,
and HES without gene abnormality such as PDGFRA, PDGFRB, orFGFR1.1 The standard therapy of HES without gene abnormality is
steroid; by contrast, the ﬁrst-line therapy of HES with gene ab-
normality is imatinib.8
Although in-depth and durable molecular responses occur with
imatinib, discontinuation of the drug can lead to relapse.6,9 In the
French series, imatinib was stopped in 11 patients - 6 of those pa-
tients subsequently relapsed.10 According to these studies, we may
presume that imatinib could suppress abnormal clones, but not
clear them out. In contrast to CML, very few cases of acquired
imatinib resistance have been reported with almost 10 years of
experience in treating FIP1L1-PDGFRA-positive disease. Most of the
cases have involved the T674I mutation within the ATP-binding
domain.9,11,12 The T674I mutation is analogous to the T315I BCR-
ABL mutation in CML which confers resistance to the tyrosine ki-
nase inhibitors imatinib, dasatinib, and nilotinib.13,14
The salvage therapy of imatinib-resistant HES has remained
unclear so far.
In this case, our laboratory could not provide the test
detecting the T674I mutation. According to the study of David M.
et al, imatinib with 400 mg per day could elicit durable hema-
tologic and cytogenetic remissions.15 However, this patient
developed resistance to imatinib 400 mg per day. Then, dasatinib
70 mg per day was prescribed but her symptoms did not
improved. Following the patient's insistence of dasatinib 50 mg
per day, we tried the combination therapy with dasatinib, ste-
roid, and hydroxyurea. Fortunately, this regimen was effective as
to this patient. We did not answer the mechanism of this salvage
therapy and just provided a feasible regimen in treating
imatinib-resistant HES.
Fig. 4. A successive CT of the chest showing regressive changes in September 2008 (After imatinib 200 mg/day by 1 year).
Fig. 5. A CT of the chest showing patchy ground glass opacities at lingual segment of LUL and LLL of lung, increased inﬁltration in the RLL of the lung when the disease deteriorated
in October 2013. (After imatinib 200 mg/day for 6 years and before imatinib 400 mg/day).
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Fig. 6. A successive CT showing. regressive changes in May 2015 (after the salvage therapy of 4 months).
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